Skip Nav Destination
Issues
15 February 2015
-
Cover Image
Cover Image
The cover shows a patient's plucked hair bulb 24 hours after receiving an infusion of DMS612, a novel bifunctional alkylating agent. Immunohistochemical staining shows γ-H2AX foci as markers of DMS-induced DNA double-strand breaks. For details, see the article by Appleman and colleagues on page 721 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR 20th Anniversary Commentary
CCR Translations
CCR Drug Updates
Molecular Pathways
Perspectives
Cancer Therapy: Clinical
Author Choice
Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
Robin L. Jones; Edward S. Kim; Pilar Nava-Parada; Salma Alam; Faye M. Johnson; Andrew W. Stephens; Ronit Simantov; Srinivasu Poondru; Rich Gedrich; Scott M. Lippman; Stan B. Kaye; Craig P. Carden
Author Choice
A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Igor Puzanov; Colin R. Lindsay; Laura Goff; Jeff Sosman; Jill Gilbert; Jordan Berlin; Srinivasu Poondru; Ronit Simantov; Rich Gedrich; Andrew Stephens; Emily Chan; T.R. Jeffry Evans
Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
Geoffrey T. Gibney; Ragini R. Kudchadkar; Ronald C. DeConti; Melissa S. Thebeau; Maria P. Czupryn; Leticia Tetteh; Cabell Eysmans; Allison Richards; Michael J. Schell; Kate J. Fisher; Christine E. Horak; H. David Inzunza; Bin Yu; Alberto J. Martinez; Ibrahim Younos; Jeffrey S. Weber
A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
Leonard J. Appleman; Sanjeeve Balasubramaniam; Robert A. Parise; Christine Bryla; Christophe E. Redon; Asako J. Nakamura; William M. Bonner; John J. Wright; Richard Piekarz; David R. Kohler; Yixing Jiang; Chandra P. Belani; Julie Eiseman; Edward Chu; Jan H. Beumer; Susan E. Bates
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard; Josep Tabernero; Filip Janku; Zev A. Wainberg; Luis Paz-Ares; Johan Vansteenkiste; Eric Van Cutsem; José Pérez-García; Anastasios Stathis; Carolyn D. Britten; Ngocdiep Le; Kirsten Carter; David Demanse; Denes Csonka; Malte Peters; Angela Zubel; Heidi Nauwelaerts; Cristiana Sessa
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Anthony W. Tolcher; Khurum Khan; Michael Ong; Udai Banerji; Vassiliki Papadimitrakopoulou; David R. Gandara; Amita Patnaik; Richard D. Baird; David Olmos; Christopher R. Garrett; Jeffrey M. Skolnik; Eric H. Rubin; Paul D. Smith; Pearl Huang; Maria Learoyd; Keith A. Shannon; Anne Morosky; Ernestina Tetteh; Ying-Ming Jou; Kyriakos P. Papadopoulos; Victor Moreno; Brianne Kaiser; Timothy A. Yap; Li Yan; Johann S. de Bono
Personalized Medicine and Imaging
Author Choice
Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy
Philip C. Schouten; Frederik Marmé; Sebastian Aulmann; Hans-Peter Sinn; Hendrik F. van Essen; Bauke Ylstra; Michael Hauptmann; Andreas Schneeweiss; Sabine C. Linn
Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Brian P. Neuman; John B. Eifler; Mark Castanares; Wasim H. Chowdhury; Ying Chen; Ronnie C. Mease; Rong Ma; Amarnath Mukherjee; Shawn E. Lupold; Martin G. Pomper; Ronald Rodriguez
Cancer Therapy: Preclinical
Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Tetje C. van der Sluis; Suzanne van Duikeren; Suzanna Huppelschoten; Ekaterina S. Jordanova; Elham Beyranvand Nejad; Arjen Sloots; Louis Boon; Vincent T.H.B.M. Smit; Marij J.P. Welters; Ferry Ossendorp; Bob van de Water; Ramon Arens; Sjoerd H. van der Burg; Cornelis J.M. Melief
Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
Elizabeth Pham; Michael J. Birrer; Scott Eliasof; Edward G. Garmey; Douglas Lazarus; Christina R. Lee; Shan Man; Ursula A. Matulonis; Christian G. Peters; Ping Xu; Carolyn Krasner; Robert S. Kerbel
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Malcolm A. Smith; C. Patrick Reynolds; Min H. Kang; E. Anders Kolb; Richard Gorlick; Hernan Carol; Richard B. Lock; Stephen T. Keir; John M. Maris; Catherine A. Billups; Dmitry Lyalin; Raushan T. Kurmasheva; Peter J. Houghton
Biology of Human Tumors
Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Michaela K. Keck; Zhixiang Zuo; Arun Khattri; Thomas P. Stricker; Christopher D. Brown; Matin Imanguli; Damian Rieke; Katharina Endhardt; Petra Fang; Johannes Brägelmann; Rebecca DeBoer; Mohamed El-Dinali; Serdal Aktolga; Zhengdeng Lei; Patrick Tan; Steve G. Rozen; Ravi Salgia; Ralph R. Weichselbaum; Mark W. Lingen; Michael D. Story; K. Kian Ang; Ezra E.W. Cohen; Kevin P. White; Everett E. Vokes; Tanguy Y. Seiwert
pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma
Melanie Ruf; Christiane Mittmann; Anna M. Nowicka; Arndt Hartmann; Thomas Hermanns; Cédric Poyet; Maries van den Broek; Tullio Sulser; Holger Moch; Peter Schraml
Author Choice
MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung
Hans-Ulrich Schildhaus; Anne M. Schultheis; Josef Rüschoff; Elke Binot; Sabine Merkelbach-Bruse; Jana Fassunke; Wolfgang Schulte; Yon-Dschun Ko; Andreas Schlesinger; Marc Bos; Masyar Gardizi; Walburga Engel-Riedel; Michael Brockmann; Monika Serke; Ulrich Gerigk; Khosro Hekmat; Konrad F. Frank; Marcel Reiser; Holger Schulz; Stefan Krüger; Erich Stoelben; Thomas Zander; Jürgen Wolf; Reinhard Buettner
Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
Mariana Varna; Guillaume Gapihan; Jean-Paul Feugeas; Philippe Ratajczak; Sophie Tan; Irmine Ferreira; Christophe Leboeuf; Niclas Setterblad; Arnaud Duval; Jérôme Verine; Stéphane Germain; Pierre Mongiat-Artus; Anne Janin; Guilhem Bousquet
DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Liam Cornell; Joanne M. Munck; Clara Alsinet; Augusto Villanueva; Laura Ogle; Catherine E. Willoughby; Despina Televantou; Huw D. Thomas; Jennifer Jackson; Alastair D. Burt; David Newell; John Rose; Derek M. Manas; Geoffrey I. Shapiro; Nicola J. Curtin; Helen L. Reeves
Letter to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds